Cellepus Therapeutics
- Biotech or pharma, therapeutic R&D
Cellepus has created precision-guided γδ1/3 CAR-T cells against solid tumors with our next generation “Zetaless” CAR signaling architecture that resists exhaustion by evading recruitment of suppression cascades that plague Cd28/41BB frameworks. Our fundamental research has immune-characterized γδ1/3 T cells' innate ability to home in and innately kill solid tumors vs. the more abundant circulating γδ2. Our manufacturing process from cord blood donors can generate a robust allogenic therapy. Additionally, through the prosecution of three cutting-edge tumor-antigen discovery campaigns, we have new TSA targets to overcome off-tumor effects. Altogether, our “turbocharged” allogenic γδ1/3 CAR Ts can tackle the solid tumor impasse.
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}